196 related articles for article (PubMed ID: 29545347)
21. CD138 shedding in plasma cell myeloma.
Grigoriadis G; Whitehead S
Br J Haematol; 2010 Aug; 150(3):249. PubMed ID: 20433680
[No Abstract] [Full Text] [Related]
22. Vascular endothelial growth factor receptor 3 is a novel marker differing CD138-positive and CD138-negative multiple myeloma cells.
Kostjukova MN; Tupitsyn NN; Karamysheva AF
Br J Haematol; 2018 Jun; 181(6):840-843. PubMed ID: 28508400
[No Abstract] [Full Text] [Related]
23. CD138+ cell separation affects cancer gene expression in human myeloma cell lines.
Sørrig R; Hermansen NE; Hother C; Gimsing P
Eur J Haematol; 2013 Aug; 91(2):187-8. PubMed ID: 23581887
[No Abstract] [Full Text] [Related]
24. [Expression and clinical significance of Notch1 on the membrane of bone marrow CD38(+)CD138(+) plasma cells in the patients with multiple myeloma].
Zhao YR; Fu R; Guan J; Gao S; Liu H; Ruan EB; Qu W; Liang Y; Wang GJ; Wang XM; Liu H; Wu YH; Song J; Wang HQ; Xing LM; Wang J; Li LJ; Shao ZH
Zhonghua Xue Ye Xue Za Zhi; 2012 Apr; 33(4):274-7. PubMed ID: 22781716
[TBL] [Abstract][Full Text] [Related]
25. Expression analysis of multiple myeloma CD138 negative progenitor cells using single molecule microarray readout.
Jacak J; Schnidar H; Muresan L; Regl G; Frischauf A; Aberger F; Schütz GJ; Hesse J
J Biotechnol; 2013 Apr; 164(4):525-30. PubMed ID: 23416329
[TBL] [Abstract][Full Text] [Related]
26. CD19-CD45 low/- CD38 high/CD138+ plasma cells enrich for human tumorigenic myeloma cells.
Kim D; Park CY; Medeiros BC; Weissman IL
Leukemia; 2012 Dec; 26(12):2530-7. PubMed ID: 22733078
[TBL] [Abstract][Full Text] [Related]
27. Isolation of Circulating Plasma Cells in Multiple Myeloma Using CD138 Antibody-Based Capture in a Microfluidic Device.
Qasaimeh MA; Wu YC; Bose S; Menachery A; Talluri S; Gonzalez G; Fulciniti M; Karp JM; Prabhala RH; Karnik R
Sci Rep; 2017 Apr; 7():45681. PubMed ID: 28374831
[TBL] [Abstract][Full Text] [Related]
28. Dynamic CD138 surface expression regulates switch between myeloma growth and dissemination.
Akhmetzyanova I; McCarron MJ; Parekh S; Chesi M; Bergsagel PL; Fooksman DR
Leukemia; 2020 Jan; 34(1):245-256. PubMed ID: 31439945
[TBL] [Abstract][Full Text] [Related]
29. MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients.
Rocci A; Gambella M; Aschero S; Baldi I; Trusolino L; Cavallo F; Gay F; Larocca A; Magarotto V; Omedè P; Isaia G; Bertotti A; Liberati AM; Catalano L; De Rosa L; Musto P; Vallone R; Falcone A; Drandi D; Ladetto M; Comoglio PM; Boccadoro M; Palumbo A
Br J Haematol; 2014 Mar; 164(6):841-50. PubMed ID: 24450886
[TBL] [Abstract][Full Text] [Related]
30. Development of Label-Free Impedimetric Immunosensors for IKZF1 and IKZF3 Femtomolar Detection for Monitoring Multiple Myeloma Patients Treated with Lenalidomide.
Abdulkarim H; Zourob M; Siaj M
Sci Rep; 2020 Jun; 10(1):10424. PubMed ID: 32591583
[TBL] [Abstract][Full Text] [Related]
31. IKAROS expression in distinct bone marrow cell populations as a candidate biomarker for outcome with lenalidomide-dexamethasone therapy in multiple myeloma.
Bolomsky A; Hübl W; Spada S; Müldür E; Schlangen K; Heintel D; Rocci A; Weißmann A; Fritz V; Willheim M; Zojer N; Palumbo A; Ludwig H
Am J Hematol; 2017 Mar; 92(3):269-278. PubMed ID: 28052520
[TBL] [Abstract][Full Text] [Related]
32. Tumor-primed natural killer cells from patients with multiple myeloma lyse autologous, NK-resistant, bone marrow-derived malignant plasma cells.
Katodritou E; Terpos E; North J; Kottaridis P; Verrou E; Gastari V; Chadjiaggelidou C; Sivakumaran S; Jide-Banwo S; Tsirogianni M; Kapetanos D; Zervas K; Lowdell MW
Am J Hematol; 2011 Dec; 86(12):967-73. PubMed ID: 21919039
[TBL] [Abstract][Full Text] [Related]
33. Multiple myeloma with CD138 changed from positive to negative: A case report.
Yu J; Tan L; Wu Q; Rao Y; Ao J; Yang W; Zou B; Chen J
Cytometry B Clin Cytom; 2021 Mar; 100(2):249-253. PubMed ID: 31967404
[TBL] [Abstract][Full Text] [Related]
34. Multiple myeloma with loss of CD138 expression in two rare metastatic localizations, peritoneum and skin.
Svrcek M; Meignin V; Brière J; Quillard J; Mariette X; Audouin J; Janin A
Histopathology; 2007 Jun; 50(7):952-4. PubMed ID: 17543089
[No Abstract] [Full Text] [Related]
35. MALAT1 long non-coding RNA is overexpressed in multiple myeloma and may serve as a marker to predict disease progression.
Cho SF; Chang YC; Chang CS; Lin SF; Liu YC; Hsiao HH; Chang JG; Liu TC
BMC Cancer; 2014 Nov; 14():809. PubMed ID: 25369863
[TBL] [Abstract][Full Text] [Related]
36. Double CD38
Mykytiv V; Alwaheed A; Mohd Hashim NA
Hematol Oncol Stem Cell Ther; 2019 Mar; 12(1):64-66. PubMed ID: 29079129
[TBL] [Abstract][Full Text] [Related]
37. [The clinical significance of decrease in CD138 positive cell ratio in multiple myeloma].
Inoue J; Ikeda M; Shingaki S; Miyazaki K; Meshitsuka S; Abe Y; Sekine R; Tsukada N; Hattori Y; Suzuki K
Rinsho Ketsueki; 2015 Nov; 56(11):2311-7. PubMed ID: 26666717
[TBL] [Abstract][Full Text] [Related]
38. Granulocyte colony stimulating factor-producing multiple myeloma associated with neutrophilia.
Kohmura K; Miyakawa Y; Kameyama K; Kizaki M; Ikeda Y
Leuk Lymphoma; 2004 Jul; 45(7):1475-9. PubMed ID: 15359652
[TBL] [Abstract][Full Text] [Related]
39. Tumor Cell-Derived Microvesicles Induced Not Epithelial-Mesenchymal Transition but Apoptosis in Human Proximal Tubular (HK-2) Cells: Implications for Renal Impairment in Multiple Myeloma.
Zhao A; Kong F; Liu CJ; Yan G; Gao F; Guo H; Guo AY; Chen Z; Li Q
Int J Mol Sci; 2017 Feb; 18(3):. PubMed ID: 28264449
[TBL] [Abstract][Full Text] [Related]
40. Cellular Proliferation by Multiplex Immunohistochemistry Identifies High-Risk Multiple Myeloma in Newly Diagnosed, Treatment-Naive Patients.
Ely S; Forsberg P; Ouansafi I; Rossi A; Modin A; Pearse R; Pekle K; Perry A; Coleman M; Jayabalan D; Di Liberto M; Chen-Kiang S; Niesvizky R; Mark TM
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):825-833. PubMed ID: 29051077
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
